M
Myron S. Cohen
Researcher at University of North Carolina at Chapel Hill
Publications - 576
Citations - 50913
Myron S. Cohen is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Population & Acquired immunodeficiency syndrome (AIDS). The author has an hindex of 103, co-authored 549 publications receiving 46021 citations. Previous affiliations of Myron S. Cohen include University of Massachusetts Medical School & Scripps Health.
Papers
More filters
Journal ArticleDOI
Prior HIV testing among STD patients in Guangdong Province, China: opportunities for expanding detection of sexually transmitted HIV infection.
Joseph D. Tucker,Li Gang Yang,Bin Yang,Darwin Young,Gail E. Henderson,Shu Jie Huang,He Kun Lu,Xiang Sheng Chen,Myron S. Cohen +8 more
TL;DR: Incomplete prior HIV screening among STD patients in China suggests the need for broadening HIV testing opportunities at STD clinics and similar clinical settings attended by those with increased sexual risk.
Journal ArticleDOI
High clade C HIV-1 viremia: how did we get here and where are we going?
TL;DR: The steady state concentration of virus in blood plasma, generally referred to as the viral ‘set point,’ correlates directly with the rate of clinical disease progression and the CD4 cell count depletion, and HIV-1 transmission probability can be correlated with the viral load in blood and genital secretions.
Journal ArticleDOI
Pharmacokinetic Modeling of Lamivudine and Zidovudine Triphosphates Predicts Differential Pharmacokinetics in Seminal Mononuclear Cells and Peripheral Blood Mononuclear Cells
Julie B. Dumond,Kuo H. Yang,Racheal N. Kendrick,Y. Sunila Reddy,Angela D. M. Kashuba,Luigi Troiani,Arlene S. Bridges,Susan A. Fiscus,Alan Forrest,Myron S. Cohen +9 more
TL;DR: In this paper, the authors used population pharmacokinetic (PK) modeling-based methods to simultaneously describe parent and intracellular metabolite PK in blood, semen, and peripheral blood mononuclear cells (PBMCs) and SMCs.
Journal ArticleDOI
Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants.
Yunda Huang,Yunda Huang,Lily Zhang,Amanda Eaton,Nonhlanhla N. Mkhize,Lindsay N. Carpp,Erika Rudnicki,Allan C. deCamp,Michal Juraska,April K. Randhawa,Adrian B. McDermott,Julie E. Ledgerwood,Philip Andrew,Shelly Karuna,Srilatha Edupuganti,Nyaradzo Mgodi,Myron S. Cohen,Lawrence Corey,Lawrence Corey,John R. Mascola,Peter B. Gilbert,Peter B. Gilbert,Lynn Morris,David C. Montefiori +23 more
TL;DR: In this paper, four different statistical approaches were applied to predict serum VRC01-mediated neutralization titer against Env-pseudotyped viruses, including breakthrough viruses isolated from AMP placebo recipients who became HIV-1 infected during the trial, using VRC1 serum concentration and neutralization potency (IC50 or IC80) of the clinical lot against the same virus.